Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 12 June
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued:
12 June 2018, London, UK - LSE
GSK announces changes to Vaccines and Global Manufacturing &
Supply leadership
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Luc
Debruyne, President, Vaccines, is to leave GSK at the end of the
year. Roger Connor, currently GSK's President, Global Manufacturing
& Supply (GMS), will become President, Vaccines on 1
September.
During a 27-year career at GSK, Luc has held a number of roles
including General Manager for the Company in the Netherlands and
Italy and Senior Vice President of the Pharmaceuticals business in
Europe. For the last 5 years he has been President, Vaccines
overseeing the successful integration of the Novartis
vaccines business, including the R&D portfolios and
manufacturing networks, aligning resources to priority projects,
preparation of the Shingrix launch and building a stronger presence
in the US.
Roger Connor has been on the Corporate Executive Team (CET) since
2012 as President, GMS and has led the strategic transformation of
GSK's supply chain to support improved quality and supply
performance. He has a proven track record of leading a complex,
global organisation, developing organisational capability and
driving cultural transformation.
With effect from 1 September, Regis Simard is appointed President,
Pharmaceutical Supply Chain and will join CET. Regis is currently SVP Global
Pharma Manufacturing and joined GSK in 2005 as a site director in
France, having previously worked in the electronics, medical
devices and pharmaceutical industries.
GSK - a
science-led global healthcare company with a special purpose: to
help people do more, feel better, live longer. For further
information please visit www.gsk.com.
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
|
|
|
|
Cautionary statement regarding forward-looking
statementsGSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D Principal risks and
uncertainties in the company's Annual Report on Form 20-F for
2017.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
12, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|